Publications by authors named "Simone Claudiani"

Claim this Profile
C
Changes in Common Blood Parameters After Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukaemia.
Fiona Fernando, Claudia Wasko, Bronwen Johns, Simone Claudiani, Afzal Khan

EJHaem· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thrombocytosis and bleeding in myeloproliferative neoplasms: exploring clinical diversity and risk of acquired von Willebrand syndrome-insights from a UK center.
Giulia Simini, Andrew Innes, Saravanan Vinayagam, Golzar Mobayen, Nilanthi Karawitage, Simone Claudiani

Res Pract Thromb Haemost· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy.
Andrew J Innes, Chloe Hayden, Victoria Orovboni, Simone Claudiani, Fiona Fernando

Leukemia· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemia.
George Nesr, Simone Claudiani, Dragana Milojkovic, Andrew Innes, Fiona Fernando

Leuk Lymphoma· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score.
Fiona Fernando, Maria Sol Andres, Simone Claudiani, Nazanin Zounemat Kermani, Giulia Ceccarelli

Cardiooncology· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-free remission in CML patients with additional chromosome abnormalities in the Philadelphia-positive clone or variant Philadelphia translocations.
Simone Claudiani, Lynette Chee, Fiona Fernando, Loretta Brown, Udayakumar M Achandira

Am J Hematol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance.
Simone Claudiani, Farhan Chughtai, Afzal Khan, Chloe Hayden, Fiona Fernando

Leukemia· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia.
Fiona Fernando, Andrew J Innes, Simone Claudiani, Angharad Pryce, Chloe Hayden

Bone Marrow Transplant· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions.
Philippa C May, Alistair G Reid, Mark E Robinson, Jamshid S Khorashad, Dragana Milojkovic, Simone Claudiani

BMC Med Genomics· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Dragana Milojkovic, Catherine J Reynolds, Diana Mūnoz Sandoval, Franziska P Pieper, Siyi Liu, Simone Claudiani

Leukemia· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies.
Lucy B Cook, Gillian O'Dell, Eleni Vourvou, Renuka Palanicawandar, Sasha Marks, Simone Claudiani

Nat Commun· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands.
Simone Claudiani, Jeroen J W M Janssen, Jenny Byrne, Graeme Smith, Nicole Blijlevens

Eur J Haematol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: results from a seroprevalence study.
Simone Claudiani, Eleanor L Parker, Dragana Milojkovic, Carolina Rosadas, Afzal Khan

Leuk Lymphoma· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors.
Simone Claudiani, Jane F Apperley, Eleanor L Parker, Federica Marchesin, Ksenia Katsanovskaja

Br J Haematol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of quantitative polymerase chain reaction for BCR-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
Katherine M Dominy, Simone Claudiani, Matthew O'Hare, Richard Szydlo, Gareth Gerrard

Br J Haematol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is COVID-19 less severe in CML patients than in those with other haematological cancers?
Simone Claudiani

Br J Haematol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis.
Simone Claudiani, Clinton C Mason, Dragana Milojkovic, Andrea Bianchi, Cristina Pellegrini

Cancers (Basel)· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.
Simone Claudiani, Jane F Apperley, Richard Szydlo, Afzal Khan, George Nesr

Br J Haematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy.
Clinton C Mason, Carme R Fiol, Monika J Baker, Elisabet Nadal-Melsio, Eva Yebra-Fernandez, Simone Claudiani

Br J Haematol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platelet function in patients with chronic myeloid leukemia treated with asciminib.
George Nesr, Mike Laffan, Simone Claudiani, Andrew Innes, Jane Apperley

Leuk Lymphoma· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prolonged treatment-free remission in chronic myeloid leukemia patients with previous kinase domain mutations.
Simone Claudiani, Jane F Apperley, Afzal Khan, Jamshid Khorashad, Dragana Milojkovic

Haematologica· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors.
Georgios Nteliopoulos, Alexandra Bazeos, Simone Claudiani, Gareth Gerrard, Edward Curry

Haematologica· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1.
Danmei Xu, Simone Claudiani, Kikkeri Naresh, Stuart Mucklow, Pratap Neelakantan

Leuk Lymphoma· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The influence of salivary amylase on total amylase elevation in CML patients treated with TKI therapy: a case series of 3 patients.
George Nesr, Simone Claudiani, Jamshid Khorashad, Jane Apperley, Dragana Milojkovic

Leuk Lymphoma· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report.
Brian Hanley, George Nesr, Eva Yebra-Fernandez, Loretta Brown, Andrea Rabitsch, Simone Claudiani

J Clin Pathol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis